Skip to main content
Premium Trial:

Request an Annual Quote

Invitrogen Completes Acquisition of BioReliance for $403.2 Million

NEW YORK, Feb. 10 (GenomeWeb News) - Carlsbad, Calif.-based Invitrogen yesterday announced the closing of its acquisition of BioReliance in an all-cash deal conducted through its subsidiary entity, Baseball Acquisition.

BioReliance, a Rockville, Md.-based contract service organization, will operate as a wholly-owned subsidiary of Invitrogen. The firm in January announced that it would close a 44-employee Worchester, Mass., facility it acquired with a merger with Q-One Biotech in September.

BioReliance shares were delisted from the Nasdaq exchange, and ceased trading at the close of business on Friday, Feb. 6.

Invitrogen announced in December that it would acquire BioReliance for $500 million. Invitrogen paid $48 per share for BioReliance's approximately 8.4 million shares, valuing today's transaction at $403,200,000.

The Scan

Germline-Targeting HIV Vaccine Shows Promise in Phase I Trial

A National Institutes of Health-led team reports in Science that a broadly neutralizing antibody HIV vaccine induced bnAb precursors in 97 percent of those given the vaccine.

Study Uncovers Genetic Mutation in Childhood Glaucoma

A study in the Journal of Clinical Investigation ties a heterozygous missense variant in thrombospondin 1 to childhood glaucoma.

Gene Co-Expression Database for Humans, Model Organisms Gets Update

GeneFriends has been updated to include gene and transcript co-expression networks based on RNA-seq data from 46,475 human and 34,322 mouse samples, a new paper in Nucleic Acids Research says.

New Study Investigates Genomics of Fanconi Anemia Repair Pathway in Cancer

A Rockefeller University team reports in Nature that FA repair deficiency leads to structural variants that can contribute to genomic instability.